PL2170952T3 - Cząsteczki wiążące specyficznie RSV i środki dla ich wytwarzania - Google Patents

Cząsteczki wiążące specyficznie RSV i środki dla ich wytwarzania

Info

Publication number
PL2170952T3
PL2170952T3 PL08766756.4T PL08766756T PL2170952T3 PL 2170952 T3 PL2170952 T3 PL 2170952T3 PL 08766756 T PL08766756 T PL 08766756T PL 2170952 T3 PL2170952 T3 PL 2170952T3
Authority
PL
Poland
Prior art keywords
rsv
producing
specific binding
binding molecules
molecules
Prior art date
Application number
PL08766756.4T
Other languages
English (en)
Inventor
Hergen Spits
Tim Beaumont
Etsuko Yasuda
Mark Jeroen Kwakkenbos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2170952T3 publication Critical patent/PL2170952T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10RNA viruses
    • C07K16/11Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL08766756.4T 2007-06-01 2008-05-30 Cząsteczki wiążące specyficznie RSV i środki dla ich wytwarzania PL2170952T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07109472A EP1997830A1 (en) 2007-06-01 2007-06-01 RSV specific binding molecules and means for producing them

Publications (1)

Publication Number Publication Date
PL2170952T3 true PL2170952T3 (pl) 2016-10-31

Family

ID=38578633

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08766756.4T PL2170952T3 (pl) 2007-06-01 2008-05-30 Cząsteczki wiążące specyficznie RSV i środki dla ich wytwarzania

Country Status (22)

Country Link
US (5) US8562996B2 (pl)
EP (3) EP1997830A1 (pl)
JP (4) JP5450395B2 (pl)
KR (2) KR101599556B1 (pl)
CN (2) CN104961825A (pl)
AU (1) AU2008257801B8 (pl)
BR (1) BRPI0812878C1 (pl)
CA (2) CA2950515A1 (pl)
CY (1) CY1117767T1 (pl)
DK (1) DK2170952T3 (pl)
ES (1) ES2575129T3 (pl)
HR (1) HRP20160632T1 (pl)
HU (1) HUE029225T2 (pl)
IL (1) IL202288A (pl)
MX (2) MX2009012843A (pl)
NZ (3) NZ621824A (pl)
PL (1) PL2170952T3 (pl)
PT (1) PT2170952E (pl)
RU (2) RU2628095C2 (pl)
SI (1) SI2170952T1 (pl)
WO (1) WO2008147196A2 (pl)
ZA (1) ZA200908320B (pl)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
EP1974017B2 (en) 2005-12-09 2023-06-21 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for influencing the stability of antibody producing cells
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP2201040A1 (en) * 2007-09-24 2010-06-30 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses thereof
EP2373689A1 (en) 2008-12-12 2011-10-12 MedImmune, LLC Crystals and structure of a human igg fc variant with enhanced fcrn binding
JP5781508B2 (ja) * 2009-07-15 2015-09-24 アイム・セラピューティクス・べー・フェー 高親和性抗体を産生させるための手段および方法
AU2015200208B2 (en) * 2009-07-15 2016-10-20 Kling Biotherapeutics B.V. Means and methods for producing high affinity antibodies
WO2011043643A1 (en) * 2009-10-06 2011-04-14 Medimmune Ltd Rsv-specific binding molecule
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CN104628850B (zh) * 2009-10-06 2020-07-28 医学免疫有限公司 Rsv-特异性结合分子
PH12012502244A1 (en) * 2010-07-09 2016-09-30 Crucell Holland Bv Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
EP2646466B1 (en) * 2010-12-02 2017-03-29 AIMM Therapeutics B.V. Means and methods for producing high affinity antibodies
US9283271B2 (en) 2010-12-17 2016-03-15 Neurimmune Holding Ag Human anti-SOD1 antibodies
BR112014010823B1 (pt) * 2011-11-07 2021-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services anticorpos que se ligam a gp41 e neutralizam o vírus da imunodeficiência humana tipo 1 (hiv-1), seus usos, molécula de ácido nucleico, vetor de expressão, composição, kit, bem como métodos de detecção de infecção pelo hiv-1 e de teste de imunógeno potencial
US9718876B2 (en) 2011-11-17 2017-08-01 Aimm Therapeutics B.V. RSV G protein specific antibodies
NZ630920A (en) * 2012-03-20 2017-01-27 Humabs Biomed Sa Antibodies that neutralize rsv, mpv and pvm and uses thereof
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
LT2950886T (lt) 2013-02-01 2020-07-10 Medimmune, Llc Respiracinio sincitinio viruso f baltymo epitopai
FI2970398T3 (fi) 2013-03-13 2024-08-06 Us Health Rsv f -prefuusioproteiineja ja niiden käyttö
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒f蛋白質的人類抗體及其使用方法
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
US9856313B2 (en) 2013-03-15 2018-01-02 Xiamen University Epitope of RSV fusion protein and antibody recognizing the same
US10047145B2 (en) 2013-07-24 2018-08-14 Humabs Biomed Sa Antibodies that potently neutralize RSV and uses thereof
WO2015037992A1 (en) 2013-09-11 2015-03-19 Aimm Therapeutics B.V. Parechovirus specific antibodies
US10556963B2 (en) 2013-12-17 2020-02-11 Aimm Therapeutics B.V. Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
EP4353316A3 (en) * 2014-01-15 2024-08-21 Medimmune Limited Rsv-specific antibodies and functional parts thereof
AU2015211480B2 (en) 2014-01-31 2020-05-14 Kling Biotherapeutics B.V. Means and methods for producing stable antibodies
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
US9340604B1 (en) * 2014-10-29 2016-05-17 Aridis Pharmaceuticals, Inc. Human monoclonal antibody specific for the F protein of respiratory syncytial virus (RSV)
JP5996707B2 (ja) * 2015-04-15 2016-09-21 メディミューン リミテド Rsv特異的結合分子
CA2989378A1 (en) 2015-06-18 2016-12-22 Vib Vzw Immunoglobulin single variable domain antibody against rsv prefusion f protein
EP3124042A1 (en) 2015-07-28 2017-02-01 VIB, vzw Immunoglobulin single variable domain antibody against rsv prefusion f protein
CA2989551A1 (en) 2015-06-24 2016-12-29 Aimm Therapeutics B.V. Aml antigens and uses thereof
JP6664467B2 (ja) 2015-08-19 2020-03-13 ファイザー・インク 組織因子経路インヒビター抗体およびその使用
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
EP3393512B1 (en) 2015-12-23 2025-11-19 Pfizer Inc. Rsv f protein mutants
US11174292B2 (en) 2016-03-29 2021-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion RSV F proteins and their use
WO2018075954A2 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
CN110035771B (zh) 2016-10-21 2024-03-08 阿迪马布有限责任公司 抗呼吸道合胞病毒抗体及其产生和使用方法
JP2020503843A (ja) 2016-10-21 2020-02-06 アディマブ, エルエルシー 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
MA51230A (fr) 2018-01-29 2021-05-05 Merck Sharp & Dohme Protéines f rsv stabilisées et leurs utilisations
US11623004B2 (en) 2018-03-16 2023-04-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions and methods for vaccination against respiratory syncytial virus infection
BR112020019938A2 (pt) 2018-04-03 2021-01-26 Sanofi polipeptídeos antigênicos de vírus sincicial respiratório
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
CN112512564A (zh) 2018-04-03 2021-03-16 赛诺菲 铁蛋白蛋白
US12534514B2 (en) 2019-04-18 2026-01-27 Fraunhofer-Gesellschaft Zur Forderung Der Angewanditen Forschung Biological and synthetic molecules inhibiting respiratory syncytial virus infection
US12024553B2 (en) 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies
US20220370495A1 (en) * 2019-08-21 2022-11-24 Board Of Regents, The University Of Texas System Immune cells for adoptive cell therapies
WO2021247712A1 (en) * 2020-06-02 2021-12-09 Battelle Memorial Institute SYSTEMS AND PROCESSES TO SCREEN FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) OF 2019 (COVID-19)
KR102467943B1 (ko) * 2020-06-25 2022-11-16 재단법인 목암생명과학연구소 항-rsv 항체 및 이를 포함하는 약학적 조성물
JP7822149B2 (ja) 2020-10-02 2026-03-02 ファイザー・インク Rsv fタンパク質生産のための細胞培養工程
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
IL320459A (en) 2022-10-27 2025-06-01 Pfizer Rna molecules encoding rsv-f and vaccines containing them
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
JP2026500218A (ja) 2022-12-11 2026-01-06 ファイザー・インク インフルエンザおよびrsvに対する免疫原性組成物
AU2024314167A1 (en) 2023-06-21 2026-02-05 Shenzhen Shenxin Biotechnology Co., Ltd. Respiratory syncytial virus (rsv) vaccine
WO2025104604A1 (en) 2023-11-14 2025-05-22 Janssen Pharmaceuticals, Inc. Anti-respiratory syncytial virus antibodies and uses thereof
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
US12383614B2 (en) 2023-12-21 2025-08-12 Yikang Biotech (Suzhou) Co., Ltd. Mutants of respiratory syncytial virus fusion proteins
WO2025186719A1 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026038177A1 (en) 2024-08-16 2026-02-19 Pfizer Inc. Immunogenic compositions and uses thereof

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1188985A (en) 1980-07-01 1985-06-18 National Research Development Corporation Production of viral antigens
DE3235924T1 (de) 1981-03-06 1983-05-05 Celltech Ltd., Slough, Berkshire Monoklonaler antikoerper
US4526934A (en) * 1982-03-19 1985-07-02 Bridgestone Tire Company Limited Branched styrene-butadiene copolymers and pneumatic tires using the same
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US5340926A (en) 1983-03-25 1994-08-23 Celltech, Limited Process for the recovery of recombinantly produced protein from insoluble aggregate
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US5332805A (en) 1984-02-03 1994-07-26 Celltech Limited Process for the recovery of recombinantly produced chymosin from insoluble aggregate
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
FR2590674B1 (fr) 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4659563A (en) 1986-01-27 1987-04-21 Miles Laboratories, Inc. High titer anti-respiratory syncytial virus intravenous immune globulin
US4717766A (en) 1986-01-27 1988-01-05 Miles Laboratories, Inc. Method of preparing high titer anti-respiratory syncytial virus intravenous immune globulin
US5271927A (en) 1986-02-13 1993-12-21 Celltech Limited Antibody conjugates with macrocyclic ligands
US5468606A (en) 1989-09-18 1995-11-21 Biostar, Inc. Devices for detection of an analyte based upon light interference
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4800078A (en) 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
GB8719041D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223254A (en) 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
KR0137963B1 (ko) 1987-12-23 1998-04-30 로버트 에이. 아미테이지 인간의 호흡기 합포체성 바이러스에 대한 당단백질 면역 단편을 함유하는 키메라(chimeric) 당단백질
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル. モリソン,シェリー ドメイン‐変性不変部を有する抗体
US5183657A (en) 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
JPH01268646A (ja) 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
US5137804A (en) 1988-05-10 1992-08-11 E. I. Du Pont De Nemours And Company Assay device and immunoassay
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5354554A (en) 1989-02-10 1994-10-11 Celltech Limited Crosslinked antibodies and processes for their preparation
US6093872A (en) 1989-05-05 2000-07-25 Systemix, Inc. Extended human hematopoiesis in a heterologous host
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5518725A (en) 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
WO1991006287A1 (en) 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5279935A (en) 1990-03-01 1994-01-18 Becton, Dickinson And Company Method of immunossay including deactivation of endogenous alkaline phosphatase
EP0481058B1 (en) 1990-05-03 1996-07-17 Systemix, Inc. Human lymphoid tissue in an immunocompromised host
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
DE69223955T2 (de) 1991-04-22 1998-08-13 Massachusetts Health Research Institute, Inc. (Mhri), Boston, Mass. Verfahren für das screening von plasma-proben für einen effektiven antikörpernachweis gegen respiratorische viren
WO1992019244A2 (en) 1991-05-01 1992-11-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
CA2044940A1 (en) 1991-06-10 1992-12-11 Inder M. Verma Transdominant negative proto-oncogene
WO1993005796A1 (en) 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
US5240694A (en) 1991-09-23 1993-08-31 University Of Virginia Combined antiviral and antimediator treatment of common colds
US5418136A (en) 1991-10-01 1995-05-23 Biostar, Inc. Devices for detection of an analyte based upon light interference
DK0614530T3 (da) 1991-11-15 1998-09-28 Cornell Res Foundation Inc Indirekte immunassay for dioxinlignende forbindelser
US20020102257A1 (en) 1998-09-21 2002-08-01 Leslie Sid Johnson Human-murine chimeric antibodies against respiratory syncytial virus
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
AU3923293A (en) 1992-03-20 1993-10-21 Immunet Human monoclonal antibodies and methods for human monoclonal antibody production
GB9207479D0 (en) 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
US6685942B1 (en) 1993-12-10 2004-02-03 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
DE69332643T2 (de) 1992-09-16 2003-11-27 The Scripps Research Institute, La Jolla Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus
WO1994015640A1 (en) 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5424189A (en) 1993-03-05 1995-06-13 Kansas State University Research Foundation Bovine respiratory syncytial virus detection and primers
EP0705109B2 (en) * 1993-05-25 2004-01-02 American Cyanamid Company Adjuvants for vaccines against respiratory syncytial virus
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
AU689489B2 (en) 1993-07-30 1998-04-02 Oravax, Inc Monoclonal IgA antibody against respiratory syncytial virus
US5506209A (en) 1994-05-26 1996-04-09 Abbott Laboratories Product for inhibition of infection of mammalian cells by respiratory syncytial virus
US5538952A (en) 1994-05-26 1996-07-23 Abbott Laboratories Inhibition of infection of mammalian cells by respiratory syncytial virus
US5538733A (en) 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5792456A (en) 1994-08-04 1998-08-11 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
EP0805678B1 (en) 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Surface-modified nanoparticles and method of making and using same
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
EP0850051A2 (en) 1995-08-31 1998-07-01 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
DE69609188T2 (de) 1995-09-18 2000-12-21 Intracel Corp., Issaquah Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
DK0885002T3 (da) 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
FR2758331B1 (fr) 1997-01-14 1999-03-05 Univ Bourgogne Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
WO1998034594A1 (en) 1997-02-06 1998-08-13 Merck & Co., Inc. Thimerosal-free preservatives for vaccines
US6117980A (en) 1997-02-21 2000-09-12 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
ATE317437T1 (de) 1997-12-01 2006-02-15 Us Gov Health & Human Serv Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
US7553487B2 (en) * 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
US7090973B1 (en) * 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
AR030019A1 (es) 1999-05-18 2003-08-13 Smithkline Beecham Corp Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m
DK1180123T3 (da) 1999-05-27 2008-10-13 Us Gov Health & Human Serv Immunkonjugater, der har höj bindingsaffinitet
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
CA2398466A1 (en) 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
WO2001059142A1 (en) 2000-02-09 2001-08-16 Medimmune, Inc. Antibody gene therapy with adeno-associated viral vectors
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
EP2341075A1 (en) 2000-03-01 2011-07-06 MedImmune, LLC Antibodies binding to the f protein of a respiratory syncytial virus (rsv)
US6565849B2 (en) 2000-03-02 2003-05-20 Medimmune, Inc. Methods of enhancing activity of vaccines and vaccine compositions
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
CA2399940A1 (en) 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
JP2003531867A (ja) 2000-05-03 2003-10-28 メディミューン,インコーポレイテッド 抗体および抗炎症薬を用いた呼吸器疾患の組合せ治療法
WO2001082965A1 (en) 2000-05-03 2001-11-08 Medimmune, Inc. Combination therapy of respiratory diseases using antibodies
EP1152199B1 (de) 2000-05-03 2005-07-27 IPV Inheidener Produktions- und Vertriebsgesellschaft mbH Thermobehälter
US20020018780A1 (en) 2000-05-25 2002-02-14 Scott Koenig Epitope-based vaccine for respiratory syncytial virus F-protein
WO2002011753A1 (en) 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
US6565888B1 (en) 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
US6699473B2 (en) * 2000-10-13 2004-03-02 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
EP2412384A1 (en) 2000-11-28 2012-02-01 MedImmune, LLC Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
JP4406206B2 (ja) 2001-04-24 2010-01-27 バイエル コーポレーション ヒトtimp−1抗体
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP2141228A1 (en) * 2001-12-18 2010-01-06 Cancer Research Technology Limited Method for the generation of proliferating and differentiating B cell lines
US6911321B2 (en) 2001-12-19 2005-06-28 Genentech, Inc. Non-human primate Fc receptors and methods of use
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
AU2003240822A1 (en) * 2002-05-30 2003-12-19 Human Genome Sciences, Inc. Antibodies that specifically bind to neurokinin b
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
CA2491471A1 (en) 2002-07-03 2004-01-15 The Trustees Of The University Of Pennsylvania Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof
WO2004010935A2 (en) 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
EP1556403A4 (en) 2002-10-03 2006-06-28 Large Scale Biology Corp MAKING MULTIMETER PROTEINS
DE60334141D1 (de) 2002-10-15 2010-10-21 Facet Biotech Corp VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
WO2004043989A2 (en) 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
US7696334B1 (en) * 2002-12-05 2010-04-13 Rosetta Genomics, Ltd. Bioinformatically detectable human herpesvirus 5 regulatory gene
GB0306618D0 (en) 2003-03-22 2003-04-30 Univ Newcastle Antibody
EP1720908A2 (en) * 2004-02-17 2006-11-15 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
WO2006034292A2 (en) 2004-09-21 2006-03-30 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
US20060083741A1 (en) 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
AU2005302453A1 (en) 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
JP2008520684A (ja) 2004-11-17 2008-06-19 アブジェニックス・インコーポレーテッド Il−13に対する完全ヒトモノクローナル抗体
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
BRPI0519596B1 (pt) 2004-12-21 2022-01-18 Astrazeneca Ab Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado
NL1031674C2 (nl) 2005-04-25 2007-04-26 Pfizer Antilichamen tegen myostatine.
EP1893647A2 (en) 2005-06-23 2008-03-05 MedImmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
EP1974017B2 (en) * 2005-12-09 2023-06-21 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for influencing the stability of antibody producing cells
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US20110008329A1 (en) 2007-06-26 2011-01-13 Medlmmune, Llc Methods of Treating RSV Infections And Related Conditions
CA2695309A1 (en) 2007-09-07 2009-03-12 Symphogen A/S Methods for recombinant manufacturing of anti-rsv antibodies
US9873957B2 (en) 2008-03-13 2018-01-23 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
WO2011043643A1 (en) 2009-10-06 2011-04-14 Medimmune Ltd Rsv-specific binding molecule
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
LT2950886T (lt) 2013-02-01 2020-07-10 Medimmune, Llc Respiracinio sincitinio viruso f baltymo epitopai
EP4353316A3 (en) 2014-01-15 2024-08-21 Medimmune Limited Rsv-specific antibodies and functional parts thereof

Also Published As

Publication number Publication date
CY1117767T1 (el) 2017-05-17
EP1997830A1 (en) 2008-12-03
KR101599556B1 (ko) 2016-03-04
HRP20160632T1 (hr) 2016-07-15
EP2170952A2 (en) 2010-04-07
EP2578600A3 (en) 2013-07-31
RU2628095C2 (ru) 2017-08-14
RU2014125126A (ru) 2015-09-20
JP2010528601A (ja) 2010-08-26
DK2170952T3 (en) 2016-06-20
CN101778866B (zh) 2014-11-26
IL202288A0 (en) 2010-06-16
MX2009012843A (es) 2010-04-21
IL202288A (en) 2016-10-31
AU2008257801B8 (en) 2014-09-11
NZ581512A (en) 2012-10-26
BRPI0812878C1 (pt) 2021-05-25
SI2170952T1 (sl) 2016-08-31
US10059757B2 (en) 2018-08-28
RU2009148886A (ru) 2011-07-20
AU2008257801A1 (en) 2008-12-04
KR101652652B1 (ko) 2016-08-30
NZ712667A (en) 2017-01-27
US9321831B2 (en) 2016-04-26
JP2014079251A (ja) 2014-05-08
US20200325213A1 (en) 2020-10-15
KR20100028592A (ko) 2010-03-12
EP2578600A2 (en) 2013-04-10
HK1146073A1 (en) 2011-05-13
RU2527067C2 (ru) 2014-08-27
BRPI0812878B1 (pt) 2020-01-21
CA2950515A1 (en) 2008-12-04
US20160244509A1 (en) 2016-08-25
CA2689290A1 (en) 2008-12-04
ZA200908320B (en) 2010-08-25
CN101778866A (zh) 2010-07-14
MX350375B (es) 2017-09-05
CN104961825A (zh) 2015-10-07
US20180327484A1 (en) 2018-11-15
AU2008257801B2 (en) 2014-08-14
US8562996B2 (en) 2013-10-22
US20140072575A1 (en) 2014-03-13
HUE029225T2 (en) 2017-02-28
PT2170952E (pt) 2016-06-16
NZ621824A (en) 2016-02-26
ES2575129T3 (es) 2016-06-24
AU2008257801A8 (en) 2014-09-11
US10730931B2 (en) 2020-08-04
BRPI0812878B8 (pt) 2020-04-22
US20100239593A1 (en) 2010-09-23
EP2170952B1 (en) 2016-03-09
CA2689290C (en) 2017-01-17
JP2017019836A (ja) 2017-01-26
WO2008147196A3 (en) 2009-02-05
JP2018196380A (ja) 2018-12-13
BRPI0812878A2 (pt) 2015-03-31
WO2008147196A2 (en) 2008-12-04
JP5450395B2 (ja) 2014-03-26
US20140377279A9 (en) 2014-12-25
KR20150036796A (ko) 2015-04-07

Similar Documents

Publication Publication Date Title
ZA200908320B (en) RSV-specific binding molecules and means for producing them
ZA200806492B (en) Binding molecules
ZA201103027B (en) Improved antibody molecules
GB0815109D0 (en) Polydialkylsiloxane-bridged bi-photochromic molecules
ZA201202502B (en) Rsv-specific binding molecule
AP2012006188A0 (en) Bispecific binding molecules for anti-angiogenesistherapy.
ZA200907116B (en) Cross-species-specific bispecific binders
GB0903325D0 (en) Antibody molecules
ZA200901815B (en) Binding molecules
EP2175884A4 (en) COMBINED THERAPIES USING GITR BINDING MOLECULES
SI2155788T1 (sl) Bispecifični vezavni element specifičen za križane vrste
ZA200905210B (en) Binding members for ige molecules
EP2245153A4 (en) IMPROVED METHODS FOR PRODUCING SPECIFIC BINDING SAVINGS
EP2222447A4 (en) CONVERSION METHOD
PL2222314T3 (pl) Zastosowanie i sposoby uzyskania rozluźnienia oskrzeli
GB0813083D0 (en) Clips
GB2451699B (en) Manifold apparatus
EP2361881A4 (en) SLIDING ELEMENT AND MANUFACTURING METHOD THEREFOR
EP2234626A4 (en) METHOD AND MEANS FOR PRODUCING BRONCHORELAXATION
ZA200905324B (en) Shape representation using fourier transforms
EP2370008A4 (en) RESTRUCTURING THE VERTEBRAL COLUMN
GB0720959D0 (en) Product authentication
TWI370107B (en) Novel methods for making and using halosilylgermanes
GB2450540B (en) Spine twister
ZA201000397B (en) Process for preparing oxazolidine-and oxazolidinone-aminodiols and related intermediates